Page 52 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

KEY MESSAGES

X A 3 month clinical trial with 335 patients comparing fixed combination to each individual
component to Dorzolamide or Timolol
X Dorzolamide Timolol Fixed Combination has greater efficacy compare monotherapy.

STRENGTHS

X DTFC is more efficient in lowering IOP than Timolol or Dorzolamide alone.
X Intraocular pressure reduction was greater on average in the combination group than in
the dorzolamide and timolol groups.

X The IOP-lowering effect of the dorzolamide-timolol combination was greater than that
of either of its components administered as monotherapy.

X The combination is generally well-tolerated and provides a convenient alternative to
concomitant therapy with its individual components.

WEAKNESSES

X The mild nature of the symptoms and the low number of discontinuations for burning
and stinging indicate that these symptoms are not a significant limitation to the use of
the combination product.

MARKETING CLAIM

X Dorzolamide-Timolol combination is more efficient in lowering IOP then Dorzolamide or
Timolol administered as monotherapy.

52